Fenwick Represents Stoke Therapeutics in its $125 Million Upsized Public Offering

Fenwick represented Stoke Therapeutics (Nasdaq: STOK), a biotechnology firm developing therapies for genetic diseases, in its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke.

J.P. Morgan Securities LLC acted as sole book-running manager for the offering. More information can be obtained from Stoke’s announcement.

The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman and Julia Forbess and associates Adam Conway, Warren Pugash, Kate Souza and Bowen Xue; and tax partner William Skinner.